Related Experiment Video
Updated: Jun 30, 2026
09:04
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
[VEGF, anti-vEGF and diseases]
1Médecine vasculaire, Hôpital européen Georges Pompidou, 24, rue Leblanc, 75015 Paris.
Bulletin De L'Academie Nationale De Medecine
|September 30, 2008
Summary
Angiogenesis, the formation of new blood vessels, is crucial for tissue oxygenation. Vascular endothelial growth factor (VEGF) drives this process, offering therapeutic potential for diseases like cancer and eye conditions.
Area of Science:
- Molecular Biology
- Physiology
- Pathology
Context:
- Angiogenesis research is rapidly advancing, identifying key vascular growth factors.
- The roles of angiogenesis in tumor growth, retinopathy, and inflammation are well-established.
- Hypoxia is a primary driver of angiogenesis, essential for oxygen and nutrient delivery.
Purpose:
- To review the fundamental mechanisms and significance of angiogenesis.
- To highlight the involvement of vascular endothelial growth factor (VEGF) in physiological and pathological angiogenesis.
- To discuss the therapeutic implications of targeting VEGF in disease.
Summary:
- Angiogenesis involves the differentiation of arteries, veins, and lymphatic vessels.
- While the adult vasculature is generally stable, angiogenesis occurs during specific physiological conditions and in disease.
- Embryonic angiogenesis mechanisms are conserved in adult physiological and pathological neoangiogenesis.
Impact:
- VEGF plays a critical role in angiogenesis.
- VEGF inhibition presents a promising therapeutic strategy for various tumoral and ocular diseases.
- Understanding angiogenesis mechanisms is vital for developing novel treatments.
More Related Videos
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...